Misonix Exhibits at the Annual Medstar Georgetown Diabetic Limb Salvage
Conference and Participates in the "Gloves on Workshops"
FARMINGDALE, N.Y., Oct. 21, 2013
FARMINGDALE, N.Y. , Oct. 21, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ:
MSON), an international surgical device company that designs, manufactures and
markets innovative therapeutic ultrasonic products for spine surgery, skull
based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic
surgery and other surgical applications, recently participated in the 2013
Diabetic Limb Salvage Conference held at the JW Marriott in Washington, DC
from October 10th – 12th, 2013.
Misonix exhibited and presented the newest addition to its wound care line of
devices, the SonicOne® O.R. Ultrasonic Surgical Debridement System. The
SonicOne O.R. is an innovative surgical device that allows surgeons to address
the challenges chronic wounds present to them, the patient, and the
health-care system. SonicOne O.R. establishes a new standard in surgical wound
bed preparation, an essential first step in the wound healing process. Use of
the SonicOne O.R. system provides controlled tissue removal, decreased healing
times, reduced bleeding and a reduction of biofilm.
In addition to exhibiting at the conference, Misonix also participated in two
"Gloves on Cadaver Workshops" on Saturday October 12th, where participants
were able to use the device in simulated scenarios. The Wound Care 101
workshop was moderated by Katherine J.S. Hubley, RN, CWCN, manager of the
Wound Care Clinic at MedStar Georgetown University Hospital and the Basic Soft
Tissue Technique workshop was moderated by Dr. John S Steinberg, DPM,
Associate Professor and Co-Director of Center for Wound Healing at MedStar
Georgetown University Hospital.
More than 100 surgeons and wound care professionals had an opportunity to
trial the SonicOne O.R. technology at the conference. Faculty member Peter A.
Blume, DPM, FACFAS, Assistant Clinical Professor of Surgery at the Yale School
of Medicine in New Haven, Connecticut stated, "SonicOne O.R. was one of the
true highlights in the teaching labs at this year's Diabetic Limb Salvage
Conference. It represents one of the newest technologies for wound debridement
and wound bed preparation and may finally allow for significant reduction in
biofilm production, which inhibits wound healing. The demonstrated safety and
efficacy of the SonicOne O.R. ultrasonic debridement system has the potential
to finally transform operative wound debridement in a way that we have not
seen in the recent past."
Michael A. McManus, Jr., President and Chief Executive Officer of Misonix
comments, "We had an extremely busy DLS meeting with approximately 100
attendees visiting our exhibit seeking a product demonstration. The awareness
of SonicOne O.R. is rapidly increasing, peer-to-peer referrals are growing and
hospitals are increasingly asking for trials in their operating rooms."
About the MedStar Georgetown Diabetic Limb Salvage Conference
The conference is intended to better equip each member of the health care team
with the education and resources needed to heal wounds and prevent
amputations. It features a prominent multidisciplinary faculty that promotes
the importance of every member of the team. The course is designed for health
care practitioners of all specialties and will focus on an evidence-based
approach to each aspect of limb salvage. The meeting format included didactic
lectures, hands-on workshops, specialty symposia, and live surgical case
demonstrations for the purpose of providing a live interactive learning
Misonix, Inc. designs, develops, manufactures and markets therapeutic
ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at
Safe Harbor Statement
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.
Misonix Contact: Investor Contact:
Richard Zaremba Joe Diaz
631-694-9555 Lytham Partners
SOURCE Misonix, Inc.
Press spacebar to pause and continue. Press esc to stop.